Test the efficacy of your compound in vitro in a rapid, reliable and cost-effective way

Our proprietary cell lines are available as “matched pairs,” i.e., cell lines and corresponding patient-derived xenografts (PDXs), and can be used in vitro, ex vivo and in vivo, with a seamless transition between assays.

With 80 proprietary cell lines derived from our portfolio of PDX models and over 200 commercial human tumor cell lines available, we offer you the opportunity to test your compound with an extensive screening approach for up to 50 cell lines.

In addition to selected clinical data and comprehensive molecular data for the originating tumor model, these cell lines are also characterized by their sensitivity for up to 240 reference agents. The cell lines are also available for comparative tumor panel screens to identify and match single-agent efficacy, similar to the NCI 60, or for combination screen approaches.

Standard or custom screening panels are available and span a wide variety of cell types.

Webinar Replay

Incorporation of PDX-based In Vitro Assays into Preclinical Oncology Programs

Watch Now »

You may also be interested in...

Charles River’s Entire Discovery Portfolio

Charles River offers the most comprehensive drug discovery service portfolio in the industry, supported by scientific excellence across major therapeutic areas and target classes.

Syngeneic Models

Charles River offers syngeneic mouse models suitable for the evaluation of immunobiological-based therapies.

Webinar Replay

View our recent webinar on cost- and time-effective methods of determining the most appropriate in vivo models for your oncology preclinical program.

Featured Story

As head of the Tumor Biology Modeling Lab, Julia Schüler, PhD, DVM, brings a breadth of experience and a plan to improve clinical success rates of our clients’ oncology discovery programs.